These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Poor-prognosis gestational trophoblastic disease: an update. Surwit EA; Alberts DS; Christian CD; Graham VE Obstet Gynecol; 1984 Jul; 64(1):21-6. PubMed ID: 6204257 [TBL] [Abstract][Full Text] [Related]
4. [Etoposide (VP-16) in gynecologic malignancy]. Kanazawa K; Moromizato H Gan To Kagaku Ryoho; 1996 Dec; 23(14):1925-8. PubMed ID: 8978799 [TBL] [Abstract][Full Text] [Related]
5. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528 [TBL] [Abstract][Full Text] [Related]
6. Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease. Gordon AN; Kavanagh JJ; Gershenson DM; Saul PB; Copeland LJ; Stringer CA Cancer; 1986 Oct; 58(7):1407-10. PubMed ID: 2427185 [TBL] [Abstract][Full Text] [Related]
7. Methotrexate, bleomycin, and Etoposide in the treatment of gestational trophoblastic neoplasia. Ngan HY; Tam KF; Lam KW; Chan KK Obstet Gynecol; 2006 May; 107(5):1012-7. PubMed ID: 16648404 [TBL] [Abstract][Full Text] [Related]
8. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities. Matsui H; Iitsuka Y; Seki K; Sekiya S Gynecol Obstet Invest; 1998; 46(1):5-8. PubMed ID: 9692333 [TBL] [Abstract][Full Text] [Related]
9. Successful salvage therapy of resistant gestational trophoblastic disease with etoposide, methotrexate, dactinomycin, vincristine, and cyclophosphamide. Gallion HH; van Nagell JR; Donaldson ES; Higgins RV Gynecol Oncol; 1989 Jul; 34(1):98-100. PubMed ID: 2544491 [TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences. Wang S; An R; Han X; Zhu K; Xue Y Gynecol Oncol; 2006 Dec; 103(3):1105-8. PubMed ID: 16870237 [TBL] [Abstract][Full Text] [Related]
11. Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT--25 years experiences of KRI-TRD. Kim SJ; Bae SN; Kim JH; Kim CT; Han KT; Lee JM; Jung JK Int J Gynaecol Obstet; 1998 Apr; 60 Suppl 1():S85-96. PubMed ID: 9833620 [TBL] [Abstract][Full Text] [Related]
13. Methotrexate monotherapy for high-risk gestational trophoblastic neoplasia after therapy with etoposide, methotrexate, and dactinomycin: a case report. Taran A; Ignatov A; Smith B; Bischoff J; Costa SD Am J Obstet Gynecol; 2008 Nov; 199(5):e6-8. PubMed ID: 18984073 [TBL] [Abstract][Full Text] [Related]
15. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia. Kohorn EI Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191 [TBL] [Abstract][Full Text] [Related]
16. High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen. Surwit EA; Childers JM J Reprod Med; 1991 Jan; 36(1):45-8. PubMed ID: 1848900 [TBL] [Abstract][Full Text] [Related]
17. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. Dobson LS; Lorigan PC; Coleman RE; Hancock BW Br J Cancer; 2000 May; 82(9):1547-52. PubMed ID: 10789722 [TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Matsui H; Suzuka K; Iitsuka Y; Seki K; Sekiya S Gynecol Oncol; 2000 Jul; 78(1):28-31. PubMed ID: 10873405 [TBL] [Abstract][Full Text] [Related]